Health Care Select Sector SPDR Fund (XLV): +5.7% Monthly Gain on Defensive Rotation
Key Takeaways
- The Health Care Select Sector SPDR Fund (XLV) is a passively managed, market-cap-weighted ETF tracking the Health Care Select Sector Index, with roughly 63 holdings and approximately $41 billion in AUM.
- XLV's latest available closing price of $167.37 is about 5.7% higher than the close roughly 30 calendar days earlier, reflecting a moderate, trend-driven ETF performance advance.
- Over the trailing quarter, the fund has risen approximately 14%, supported by large-cap pharmaceutical leadership and a defensive rotation into health care.
- Concentrated portfolio holdings such as Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV) heavily influence returns, while UnitedHealth Group (UNH) and managed-care peers add policy sensitivity.
- Key investment themes include GLP-1 weight-management demand, biopharma M&A, drug pricing debates, and sector rotation away from stretched technology valuations.
XLV ETF Overview
The fund, issued by State Street Global Advisors, seeks to track the Health Care Select Sector Index, which consists of S&P 500 companies classified within the health care sector. Launched in 1998, XLV uses a passive, market-cap-weighted replication strategy, normally investing at least 95% of total assets in index securities, and is classified as non-diversified.
Portfolio data shows approximately 63 holdings, an expense ratio of 0.08%, and roughly $41 billion in assets. The largest positions are Eli Lilly (LLY) near 16% of assets, Johnson & Johnson (JNJ) near 10.6%, AbbVie (ABBV) near 7.7%, UnitedHealth Group (UNH) near 6.5%, and Merck (MRK) near 5.5%. The top ten positions represent more than 60% of the portfolio.
Sector exposure is concentrated in large-cap pharmaceuticals at roughly 38%, followed by health care providers and services near 19%, biotechnology near 18%, health care equipment and supplies near 15%, and life sciences tools and services near 9%. This structure gives mega-cap drugmakers an outsized role in fund performance while limiting exposure to smaller biotechnology names.
The Broader Health Care Landscape
Health care currently occupies a middle ground between defensive revenue stability and innovation-led growth. Medical demand is relatively steady across economic cycles, while drug development, medical devices, and data-driven diagnostics offer structural growth. After a period of relative underperformance and historically wide valuation discounts, the sector has attracted investors looking for lower-volatility equity exposure.
The macroeconomic environment has reinforced that shift. A more measured interest-rate path supports longer-duration segments such as biotechnology, where cash flows are discounted further into the future, while caution around elevated technology valuations has encouraged defensive rotation. These market trends have favored the large-cap, cash-generative franchises that dominate XLV's portfolio.
On the industry side, the GLP-1 diabetes and weight-management market remains a central growth driver. Innovation in oncology, immunology, surgical robotics, and AI-assisted drug discovery continues to draw capital, and biopharma M&A has reinforced pipeline development. Offsetting themes include drug pricing negotiations, Medicare and Medicaid policy changes, patent expirations, and managed-care margin scrutiny, all of which can create periodic volatility. I also checked this using Tickeron’s AI Screener to see how the sector compares to others in the industry.
Recent Performance Snapshot
XLV's latest available closing price of $167.37 compares with about $158.29 roughly 30 calendar days earlier, a gain of approximately 5.7%. The move was gradual rather than sharp: the fund consolidated after an early-summer advance, pulled back modestly in mid-July, and then recovered toward the upper end of its recent range.
The trailing three-month picture is stronger. XLV has climbed roughly 14% from around $146.63 roughly three months earlier, reflecting a broad re-rating of large-cap health care rather than a single event. Eli Lilly (LLY) has been a primary contributor as investors focus on GLP-1 demand. Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck (MRK) also carry meaningful weight. UnitedHealth Group (UNH) and other managed-care providers have tempered some upside amid policy and utilization debates. With more than 60% of assets in the top ten holdings, individual large-cap moves translate quickly into fund performance.
Using AI Tools in My Research
In my own analysis, I turned to Tickeron’s AI Screener to quickly scan for comparable health care names and confirm the sector trends I was seeing. The platform helps surface ideas using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. Industry and performance filters allow users to isolate ideas within specific sectors such as health care and build focused, comparable watchlists. Explore the AI Screener to support your research process.
2026 Outlook and Key Factors to Monitor
Several structural factors are likely to shape the industry outlook for XLV in 2026. Drug pricing legislation and changes to Medicare and Medicaid policy remain central policy risks. The pace of GLP-1 market expansion, competitive dynamics, and manufacturing capacity will be important for the fund's largest pharmaceutical holdings, while patent expirations and late-stage pipeline readouts could shift sentiment across large-cap pharma and biotechnology.
Investors may also monitor biopharma M&A activity, managed-care medical costs and utilization trends, and the interest-rate path, which remains relevant for longer-duration biotechnology exposure. Capital flows into health care ETFs and the durability of defensive rotation will help determine whether the sector's recent relative strength continues. Because XLV is a concentrated sector fund, its performance is tied closely to the earnings power and regulatory environment of a relatively small number of large-cap companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.
XLV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for XLV turned positive on August 10, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on XLV as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 267 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for XLV moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XLV broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement